Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide produced by the body as part of its endocannabinoid-related signaling system, playing a role in maintaining cellular balance during stress and inflammation. Research suggests that PEA may help modulate immune responses and support nerve function by acting on peroxisome proliferator-activated receptors (PPAR-alpha) and influencing mast cell activity, which are key players in inflammatory and pain pathways. Studies indicate that micronized and ultra-micronized forms of PEA, which improve bioavailability, have shown promising results in clinical trials examining chronic pain conditions, including fibromyalgia and neuropathic discomfort, with generally favorable safety profiles noted across multiple studies. While the body of evidence continues to grow, PEA has attracted considerable scientific interest as a well-tolerated compound worthy of further investigation.
Compare this supplementResearch suggests that palmitoylethanolamide (PEA) may offer meaningful pain relief across several conditions, includ...
View studies →Research suggests that palmitoylethanolamide (PEA) has meaningful anti-inflammatory properties, with the available ev...
View studies →Research suggests that palmitoylethanolamide (PEA), typically studied in combination with acetyl-L-carnitine rather t...
View studies →Research suggests that palmitoylethanolamide (PEA) may support aspects of nerve function, though the evidence is limi...
View studies →Research suggests that PEA interacts meaningfully with immune and inflammatory signaling pathways, though the availab...
View studies →These are commonly referenced dosage ranges for this supplement. They are not medical recommendations. Always consult a healthcare provider before supplementing.
| Form | Dose range | Frequency | Studied for | Source |
|---|---|---|---|---|
| Capsule | 600 mg | Three times daily | acute or severe neuropathic pain, sciatic pain | Higher dose protocol observed in some RCTs for sciatic and acute pain conditions |
| Capsule | 1,200 mg | Daily | chronic pain, fibromyalgia, inflammation | Standard total daily dose used across multiple RCTs, often split as 600 mg twice daily |
| Capsule | 300–600 mg | Twice daily | chronic pain, fibromyalgia, neuropathic pain | Common in clinical trials using micronized/ultramicronized PEA (m-PEA/um-PEA) |
| Capsule | 300 mg | Daily | immune function, general anti-inflammatory support | Lower maintenance dose referenced in some observational and pilot studies |
| Powder | 400–600 mg | Twice daily | nerve function, anti-inflammatory support | Ultramicronized powder form used in clinical studies for enhanced bioavailability |